Status:
TERMINATED
A Study of 2 Doses of MAP0010 in Asthmatic Children
Lead Sponsor:
Allergan
Collaborating Sponsors:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Conditions:
Asthma
Eligibility:
All Genders
12-8 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.
Eligibility Criteria
Inclusion
- Completed 12 weeks of treatment in the MAP0010-CL-P301 study.
- Patient, parent, and guardian (as appropriate) are willing for child to undergo all study procedures and willing to sign the informed consent and assent, as appropriate.
Exclusion
- Less than 80% compliance with either study treatment and/or other study procedures (e.g., completion of symptom e-diary) in the MAP0010-CL-P301 Study.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT00697697
Start Date
April 1 2008
End Date
December 1 2009
Last Update
January 9 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.